Khan S, Tøndervik A, Sletta H, Klinkenberg G, Emanuel C, Onsøyen E, Myrvold R, Howe RA, Walsh TR, Hill KE, Thomas DW. Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41. doi: 10.1128/AAC.00525-12. Epub 2012 Jul 23. External link to Pubmed.gov Abstract The uncontrolled, often inappropriate use of antibiotics has resulted in the increasing prevalence of antibiotic-resistant pathogens, with […]
This author has yet to write their bio.Meanwhile lets just say that we are proud rogerhenriksen contributed a whooping 21 entries.
Entries by rogerhenriksen
Philip Rye (1962) came to AlgiPharma in 2012. Astrid Hilde Myrset (1956) is a biochemist by training, and joined AlgiPharma in 2012.
AlgiPharma has together with partners Smerud Medical Research and Simbec Research been awarded a EUROSTARS grant for a €4,6 million project.
AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine.
AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (Oligo-G) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
AlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.
Oligo-G CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.
A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.
The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.
AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.
Phone: +47 67545770